AR014459A1 - Un anticuerpo monoclonal para la il-12 humana, hibridoma que produce a dicho anticuerpo, composicion farmaceutica que comprende al citado anticuerpo, y uso de dicho anticuerpo para la preparacion de medicamentos - Google Patents

Un anticuerpo monoclonal para la il-12 humana, hibridoma que produce a dicho anticuerpo, composicion farmaceutica que comprende al citado anticuerpo, y uso de dicho anticuerpo para la preparacion de medicamentos

Info

Publication number
AR014459A1
AR014459A1 ARP990100251A ARP990100251A AR014459A1 AR 014459 A1 AR014459 A1 AR 014459A1 AR P990100251 A ARP990100251 A AR P990100251A AR P990100251 A ARP990100251 A AR P990100251A AR 014459 A1 AR014459 A1 AR 014459A1
Authority
AR
Argentina
Prior art keywords
antibody
antibodies
human
heterodimer
produces
Prior art date
Application number
ARP990100251A
Other languages
English (en)
Spanish (es)
Inventor
Maurice Kent Gately
David Howard Presky
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22106938&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR014459(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR014459A1 publication Critical patent/AR014459A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP990100251A 1998-01-23 1999-01-22 Un anticuerpo monoclonal para la il-12 humana, hibridoma que produce a dicho anticuerpo, composicion farmaceutica que comprende al citado anticuerpo, y uso de dicho anticuerpo para la preparacion de medicamentos AR014459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7233398P 1998-01-23 1998-01-23

Publications (1)

Publication Number Publication Date
AR014459A1 true AR014459A1 (es) 2001-02-28

Family

ID=22106938

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP990100251A AR014459A1 (es) 1998-01-23 1999-01-22 Un anticuerpo monoclonal para la il-12 humana, hibridoma que produce a dicho anticuerpo, composicion farmaceutica que comprende al citado anticuerpo, y uso de dicho anticuerpo para la preparacion de medicamentos
ARP070102968A AR061801A2 (es) 1998-01-23 2007-07-03 Un anticuerpo monoclonal para la il-12 humana composicion farmaceutica que comprende al citado anticuerpo y uso de dicho anticuerpo para la preparacion de medicamentos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070102968A AR061801A2 (es) 1998-01-23 2007-07-03 Un anticuerpo monoclonal para la il-12 humana composicion farmaceutica que comprende al citado anticuerpo y uso de dicho anticuerpo para la preparacion de medicamentos

Country Status (18)

Country Link
US (1) US6225117B1 (cg-RX-API-DMAC10.html)
EP (2) EP1049717B1 (cg-RX-API-DMAC10.html)
JP (3) JP4481489B2 (cg-RX-API-DMAC10.html)
KR (1) KR100764256B1 (cg-RX-API-DMAC10.html)
CN (2) CN101274962A (cg-RX-API-DMAC10.html)
AR (2) AR014459A1 (cg-RX-API-DMAC10.html)
AT (2) ATE553129T1 (cg-RX-API-DMAC10.html)
AU (1) AU759624B2 (cg-RX-API-DMAC10.html)
BR (1) BR9907743A (cg-RX-API-DMAC10.html)
CA (1) CA2318052C (cg-RX-API-DMAC10.html)
CY (2) CY1106594T1 (cg-RX-API-DMAC10.html)
DE (1) DE69935574T2 (cg-RX-API-DMAC10.html)
DK (2) DK1049717T3 (cg-RX-API-DMAC10.html)
ES (2) ES2284242T3 (cg-RX-API-DMAC10.html)
PT (2) PT1049717E (cg-RX-API-DMAC10.html)
TR (1) TR200002145T2 (cg-RX-API-DMAC10.html)
WO (1) WO1999037682A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA99452B (cg-RX-API-DMAC10.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399379B1 (en) 1992-09-29 2002-06-04 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p35 subunit expression
WO2003104495A1 (en) * 2002-06-11 2003-12-18 Isis Pharmaceuticals, Inc. METHODS FOR BLOCKING ADIPOCYTE DIFFERENTIATION AND TRIGLYCERIDE ACCUMULATION WITH INTERLEUKIN 12 p35 INHIBITORS
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7026456B1 (en) * 1998-01-23 2006-04-11 Hoffman-La Roche, Inc. Antibodies against human IL-12
US6448081B1 (en) 2001-05-07 2002-09-10 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p40 subunit expression
DK1137766T3 (da) * 1998-12-09 2006-01-30 Protein Design Labs Inc Anvendelse af IL-12-antistoffer til behandling af psoriasis
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
EP1259544B1 (en) * 2000-02-11 2011-08-24 Biogen Idec MA Inc. Heterologous polypeptide of the tnf family
US6348316B1 (en) 2000-04-12 2002-02-19 Cedars-Sinai Medical Center Genetic testing for determining the risk of pouchitis development
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
WO2002097048A2 (en) * 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
CA2512138C (en) * 2002-12-30 2013-07-16 Biogen Idec Ma Inc. Kim-1 antagonists and use to modulate immune system
EP1711527A4 (en) * 2003-12-15 2008-09-03 Dendreon Corp HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS
GB0329146D0 (en) * 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
CA2591813A1 (en) 2004-12-21 2006-06-29 Centocor, Inc. Anti-il-12 antibodies, epitopes, compositions, methods and uses
EP1865985B1 (en) 2005-03-02 2010-08-25 Biogen Idec MA Inc. Kim-1 antibodies for treatment of th2-mediated conditions
CN103145837A (zh) * 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) * 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
WO2008088823A2 (en) 2007-01-16 2008-07-24 Abbott Laboratories Methods for treating psoriasis
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
KR20100126515A (ko) 2008-03-18 2010-12-01 아보트 러보러터리즈 건선의 치료방법
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
MX2011005672A (es) * 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
AU2010291927A1 (en) * 2009-09-14 2012-04-12 AbbVie Deutschland GmbH & Co. KG Methods for treating psoriasis
CN103275222B (zh) * 2013-05-15 2014-04-16 中山康方生物医药有限公司 一种阻断白介素12 p40功能的单克隆抗体及其编码基因和应用
EP3436477A2 (en) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
TW201922780A (zh) * 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019220412A2 (en) 2018-05-18 2019-11-21 Janssen Biotech, Inc. Safe and effective method of treating lupus with anti-il12/il23 antibody
HUE063462T2 (hu) 2018-09-24 2024-01-28 Janssen Biotech Inc A colitis ulcerosa kezelésének biztonságos és hatékony eljárása anti-IL12/IL23 antitesttel
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
US5780597A (en) 1989-12-22 1998-07-14 Hoffmann-La Roche Inc. Monoclonal antibodies to cytotoxic lymphocyte maturation factor
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US5536657A (en) 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7119248B1 (en) * 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US5853721A (en) * 1995-01-31 1998-12-29 Hoffmann-La Roche Inc. Antibody to interleukin-12 receptor
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
US5809360A (en) * 1996-08-07 1998-09-15 Agfa Division - Bayer Corporation Cassette for storing and accessing plates within an automated plate handler
AU734758B2 (en) * 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies

Also Published As

Publication number Publication date
CN100374466C (zh) 2008-03-12
CY1106594T1 (el) 2012-01-25
EP1049717A2 (en) 2000-11-08
JP4481489B2 (ja) 2010-06-16
CN101274962A (zh) 2008-10-01
JP2002501085A (ja) 2002-01-15
DE69935574D1 (de) 2007-05-03
KR100764256B1 (ko) 2007-10-05
ATE357459T1 (de) 2007-04-15
CN1288468A (zh) 2001-03-21
JP2013139458A (ja) 2013-07-18
US6225117B1 (en) 2001-05-01
WO1999037682A3 (en) 1999-11-18
DE69935574T2 (de) 2007-12-06
EP1818343A3 (en) 2007-08-22
EP1818343A2 (en) 2007-08-15
CA2318052A1 (en) 1999-07-29
JP2009197008A (ja) 2009-09-03
TR200002145T2 (tr) 2000-11-21
ES2284242T3 (es) 2007-11-01
DK1818343T3 (da) 2012-07-16
EP1049717B1 (en) 2007-03-21
ES2386262T3 (es) 2012-08-14
EP1818343B1 (en) 2012-04-11
KR20010034315A (ko) 2001-04-25
ZA99452B (en) 1999-07-23
CY1112927T1 (el) 2016-04-13
BR9907743A (pt) 2000-10-17
PT1818343E (pt) 2012-07-12
WO1999037682A2 (en) 1999-07-29
PT1049717E (pt) 2007-05-31
AU2517799A (en) 1999-08-09
CA2318052C (en) 2012-07-03
ATE553129T1 (de) 2012-04-15
DK1049717T3 (da) 2007-07-30
AU759624B2 (en) 2003-04-17
AR061801A2 (es) 2008-09-24

Similar Documents

Publication Publication Date Title
BR9907743A (pt) Anticorpos contra a il-12 humana
AR048912A1 (es) Inmunoglobulinas anti-nogo
ECSP15017314A (es) Formulacion de anticuerpos
DOP2019000280A (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
CL2010000790A1 (es) Anticuerpos monoclonales que se unen a integrina alfa-nu-beta6 (atcc pta-3898) composicion; hibridoma que lo produce; usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros (div.sol.no. 513-03).
MX2021004779A (es) Anticuerpos cd47 novedosos y metodos para usarlos.
BRPI0821168B8 (pt) anticorpo isolado que se liga ao il-21 humano, ou um fragmento deste, usos de dito anticorpo ou fragmento, e, hibridoma
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
ES2191016T3 (es) Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
WO2004029092A8 (fr) Anticorps pour adcc et induisant la production de cytokines.
DE69934515D1 (de) Humanisierte monoklonale integrin antikörper
ECSP034772A (es) Antagonistas de mch y su uso en el tratamiento de obesidad
EA201300022A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
AR054175A1 (es) Nuevos anticuerpos anti-igf-ir y usos de los mismos
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
SG163615A1 (en) Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
AR066306A1 (es) Conjunto de partes para el tratamiento del cancer o enfermedades infecciosas. composicion farmaceutica- usos
HRP20211773T1 (hr) Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
JP2017518258A5 (cg-RX-API-DMAC10.html)
PE20091327A1 (es) Composicion farmaceutica que comprende anticuerpos monoclonales
JP2019521649A5 (cg-RX-API-DMAC10.html)
ITMI20031127A1 (it) Anticorpi anti-hgf-r e loro uso
AR029619A1 (es) Vacuna
CL2022003715A1 (es) Tubulisinas y conjugados de proteinas-tubulisina
MX2021001305A (es) Anticuerpos anti-cxcr2 y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant, registration